Fluvoksamin

Fluvoksamin
(IUPAC) ime
	(E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-2-aminoethyl oxime
Klinički podaci
Identifikatori
CAS broj	54739-18-3
ATC kod	N06AB08
PubChem	5324346
DrugBank	APRD00425
ChemSpider	4481878
UNII	O4L1XPO44W
KEGG	D07984
ChEMBL	CHEMBL814
Hemijski podaci
Formula	C15H21F3N2O2
Mol. masa	318.335
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+ ; Key: CJOFXWAVKWHTFT-XSFVSMFZSA-N
Farmakokinetički podaci
Bioraspoloživost	77%
Metabolizam	Hepatički
Poluvreme eliminacije	15.6 sati
Izlučivanje	Renalno
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Samo na recept (S4) (AU) ℞-only (SAD)
Način primene	Oralno

Fluvoksamin (Luvoks) je antidepresiv koji deluje kao selektivni inhibitor preuzimanja serotonina (SSRI). Fluvoksamin je prvo bio odobren od strane FDA 1993 za lečenje opsesivno kompulzivnog poremećaja.^[6] Fluvoksamin CR (kontrolisano oslobađanje) je odobren za lečenje socijalne fobije.^[7] Fluvoksamin se takođe propisuje za lečenje kliničke depresije i anksioznih poremećaja, kao što su generalizovani anksiozni poremećaj, panični poremećaj, i posttraumatski stresni poremećaj.^[8]

Hemija

Fluvoksamin je jedan od samo dva SSRI liganda (zajedno sa alaproklatom^[9]^[10]) koje ima monockiličnu strukturu.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ „FDA Advisory Committee Recommends Luvox (Fluvoxamine) Tablets for Obsessive Compulsive Disorder, - Free Online Library”. Arhivirano iz originala na datum 2012-10-23. Pristupljeno 06. 05. 2011.
↑ Stahl, S. Stahl's Essential Psychopharmacology: The Prescriber's Guide. Cambridge University Press. New York, NY. 2009. pp.215
↑ Karen J. McClellan, David P. Figgitt (2000). „Fluvoxamine An Updated Review of its Use in the Management of Adults with Anxiety Disorders”. Adis Drug Evaluation 60 (4): 925–954.
↑ A Wilkinson, M Courtney, A Westlind-Danielsson, G Hallnemo and K E Akerman (December 1994). „Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow”. JPET 271 (3): 1314–1319.
↑ K L Nicholson and R L Balster (2003-04-23). „Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats”. Psychopharmacology.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[urlFDA-6] „FDA Advisory Committee Recommends Luvox (Fluvoxamine) Tablets for Obsessive Compulsive Disorder, - Free Online Library”. Arhivirano iz originala na datum 2012-10-23. Pristupljeno 06. 05. 2011.

[Stahl,_S._Stahl's_Essential_Psychopharmacology_2009._pp.215-7] Stahl, S. Stahl's Essential Psychopharmacology: The Prescriber's Guide. Cambridge University Press. New York, NY. 2009. pp.215

[8] Karen J. McClellan, David P. Figgitt (2000). „Fluvoxamine An Updated Review of its Use in the Management of Adults with Anxiety Disorders”. Adis Drug Evaluation 60 (4): 925–954.

[9] A Wilkinson, M Courtney, A Westlind-Danielsson, G Hallnemo and K E Akerman (December 1994). „Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow”. JPET 271 (3): 1314–1319.

[10] K L Nicholson and R L Balster (2003-04-23). „Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats”. Psychopharmacology.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]